Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	150080-09-4
Formula :	C₁₀H₂₃BN₂O₆S
M.W :	310.17
SMILES Code :	CS(=O)(O)=O.CC(C)[C@H](N)C(N1[C@H](B(O)O)CCC1)=O
Synonyms :	PT100 mesylate; Val-boroPro mesylate; Talabostat (mesylate)
MDL No. :	MFCD13194906
InChI Key :	OXYYOEIGQRXGPI-WSZWBAFRSA-N
Pubchem ID :	11522448

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P280-P301+P312-P302+P352-P305+P351+P338

4T1 cells	1.39 µg/mL		To evaluate the cytotoxicity of TRPP in 4T1 cells, the results showed that TRPP exhibited potent cytotoxicity with an IC50 of 1.39 µg/mL.	PMC10091884
CD4+ T cells	40 ng HIVp24 per million cells	6 days	To detect the effect of CARD8 deletion on HIV infection, the results showed that CARD8 deletion increased the susceptibility of CD4+ T cells to HIV infection.	PMC10919936
Human aortic endothelial cells (HAECs)	5 µM	16-18 hours	To validate whether HAECs can undergo inflaμMasome-driven pyroptosis in response to VbP. Results showed that VbP induced cell membrane rupture, GSDMD cleavage, and CASP1 activation, indicating that HAECs can undergo pyroptosis.	PMC9499823
A549 cells	5 µM	16 hours	To test the response of CARD8 to VbP in A549 cells. Results showed that IL-18 secretion induced by VbP was significantly reduced in CARD8 knockout cells, indicating that CARD8 plays an important role in VbP-induced inflaμMasome activation.	PMC9499823
Senescent fibroblasts (SFs)	200 μg	48 hours	To evaluate the effect of nanoparticles on SFs, the results showed that PARP1@PLS-PT100 nanoparticles significantly reduced the number of SFs and decreased the expression of SASPs and inflaμMatory factors.	PMC8728814
Bone marrow-derived macrophages (BMDMs)	0.3, 3, 30 μM	24 hours	To evaluate the effect of Talabostat on NLRP1 inflaμMasome activation, results showed that Nlrp3−/− BMDMs exhibited a significant increase in IL-1β secretion at low doses of Talabostat stimulation, and the LDH levels indicative of cell membrane rupture were also significantly elevated.	PMC6841710
HEK ASC-GFP reporter cells	0.3, 3, 30 μM	16 hours	To evaluate the sensitivity of different NLRP1 proteins to Talabostat-induced inflaμMasome formation, results showed that HEK reporters expressing NLRP1A exhibited a significant reduction in ASC speck formation in response to Talabostat, while those expressing NLRP1BC57B6 or NLRP1B129S showed no significant difference.	PMC11618613
THP-1 macrophages	2 μM	24 hours	To study the effects of Val-boroPro on IL-1β expression and secretion, results showed that Val-boroPro significantly increased IL-1β secretion.	PMC5477230
primary mouse bone marrow derived macrophages (mBMDMs)	2 μM	24 hours	To study the effects of Val-boroPro on cytotoxicity, results showed that Val-boroPro induced LDH release.	PMC5477230
primary human peripheral blood mononuclear cells (hPBMCs)	2 μM	24 hours	To study the effects of Val-boroPro on cytotoxicity, results showed that Val-boroPro induced LDH release.	PMC5477230
RAW 264.7 macrophages	2 μM	24 hours	To study the effect of Talabostat on macrophage pyroptosis, results showed that Nlrp1b-deficient macrophages were resistant to Talabostat-induced pyroptosis	PMC5856610
HEK 293T cells	5 μM	24 hours	To study the effect of Talabostat on HEK 293T cell pyroptosis, results showed that HEK 293T cells expressing Nlrp1b and procaspase-1 were sensitive to Talabostat	PMC5856610
myeloma cells	0.1–100 μmol/l	5–7 days	PT-100 had no direct effect on myeloma cells cultured alone but significantly inhibited survival of myeloma cells cocultured with osteoclasts.	PMC2748971
osteoclast precursors	0.1–1 μmol/l	10 days	PT-100 significantly inhibited osteoclast differentiation, reducing the number of multinucleated TRAP-positive osteoclasts.	PMC2748971

BALB/c mice	4T1 tumor model	Intravenous injection	50 mg/kg/d	Once daily for 10 days	To evaluate the antitumor activity of DPPA-TRPP/Tab in the 4T1 tumor model, the results showed that DPPA-TRPP/Tab significantly suppressed tumor growth with a complete tumor regression (CR) ratio of 60%.	PMC10091884
Humanized mice	NSG-SGM3 mice	Retro-orbital injection	DPPA: 0.5 mg/kg, DOX: 0.5 mg/kg, Tab: 1.0 mg/kg	Single dose	To evaluate the role of the CARD8 inflammasome in CD4+ T cell loss during HIV infection, the results showed that CARD8 deletion delayed the loss of CD4+ T cells.	PMC10919936
BALB/c mice	4T1 breast cancer model	Oral	10 ng p24/mouse	Single injection	Inhibit collagen deposition and enhance the efficacy of anti-PD-1 immunotherapy	PMC11110954
Mice	Fap/C0//C0 mice	Oral		22 weeks	Talabostat markedly improved glucose homeostasis in both Fap+/+ and Fap/C0//C0 mice, independent of FGF21 or FAP.	PMC6323180
mice	Casp1−/− knockout mice	oral	High-fat diet (60 Kcal%)	7 days before and 7 days after	To study the effects of Val-boroPro on the immune system, results showed that Casp1?/? mice did not show elevation of G-CSF and CXCL1/KC after Val-boroPro treatment.	PMC5477230
Mice	Diet-induced obese mice	Oral gavage	5 mg/kg	Single dose	To evaluate the impact of Talabostat on metabolic regulation, results showed that Talabostat significantly reduced body weight, food intake, adiposity, increased energy expenditure, improved glucose tolerance and insulin sensitivity, and lowered cholesterol levels.	PMC5034526
mice	C57BL/6J and 129S6 mice	oral	3 mg/kg or 10 mg/kg	five times per week for 6 weeks	To study the effect of Talabostat on serum levels of G-CSF and CXCL1/KC in mice, results showed that Talabostat significantly increased the levels of these cytokines	PMC5856610
SCID-hu mice	myeloma model	oral	10 mg/kg/day	for 3 consecutive days	PT-100 significantly reduced myeloma tumour burden and bone disease, inhibiting osteoclast activity and bone resorption.	PMC2748971

{[proInfo.proName]}

CAS No.: 150080-09-4

{[proInfo.proName]}

CAS No.: 150080-09-4

Alternative Products

Product Details of Talabostat mesylate

Safety of Talabostat mesylate

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00489710	Kidney Cancer	Phase 2	Withdrawn(Terminated for safet... More >>y reasons) Less <<	-	-
NCT02083120	Pulmonary Disease, Chronic Obs... More >>tructive Less <<	Not Applicable	Active, not recruiting	November 2018	Germany ... More >> Helios Klinik Ambrock Hagen, NRW, Germany, 58091 Less <<
NCT00083239	Melanoma Skin... More >> Cancer Less <<	Phase 2	Completed	-	United States, Georgia ... More >> Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322-1013 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109-0473 United States, New Hampshire Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756-0001 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213-2582 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75246 Less <<
NCT00080080	Lung Cancer	Phase 2	Completed	-	United States, Florida ... More >> Cancer Center of Florida Ocoee, Florida, United States, 34761 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan Van Elslander Cancer Center Grosse Pointe Woods, Michigan, United States, 48236 United States, New York New York Oncology/Hematology--Albany Regional Cancer Center Albany, New York, United States, 12208 Mt. Sinai School of Medicine New York, New York, United States, 10029 USB Cancer Center-- Nyack Hospital Nyack, New York, United States, 10960 United States, Ohio Dayton Oncology & Hematology Kettering, Ohio, United States, 45409 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75246 Tyler Cancer Center Tyler, Texas, United States, 75702 United States, Washington Cancer Care Northwest Spokane, Washington, United States, 99218 Less <<
NCT00083252	Melanoma Skin... More >> Cancer Less <<	Phase 2	Completed	-	United States, Arkansas ... More >> University of Arkansas Medical Sciences Little Rock, Arkansas, United States, 72205 United States, California Cancer Institute Medical Group, Inc. Santa Monica, California, United States, 90404 United States, Colorado University of Colorado Health Sciences Center Aurora, Colorado, United States, 80045 United States, Florida Cancer Center of Florida Ocoee, Florida, United States, 34761 United States, Indiana Indiana Hematology Oncology Consultants Indianapolis, Indiana, United States, 46202 United States, New Mexico New Mexico Cancer Center Alliance Albuquerque, New Mexico, United States, 87106 United States, New York NYU School of Medicine New York, New York, United States, 10016 Fifth Avenue Medical Healthcare New York, New York, United States, 10128 United States, North Carolina Carolinas Medical Center Charlotte, North Carolina, United States, 28203 United States, South Carolina Cancer Center of the Carolinas Greenville, South Carolina, United States, 29615 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75246 Tyler Cancer Center Tyler, Texas, United States, 75702 United States, Washington Cancer Care Northwest Research Spokane, Washington, United States, 99218 Less <<
NCT00086203	Chronic Lymphocytic Leukemia	Phase 2	Completed	-	United States, Arkansas ... More >> University of Arkansas for Medical Science Little Rock, Arkansas, United States, 72205 United States, Florida Ocala Oncology Center Ocala, Florida, United States, 34474 Gulfcoast Oncology Associates St. Petersburg, Florida, United States, 33705 United States, Indiana Indiana Oncology/Hematology Consultants Indianapolis, Indiana, United States, 46202 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Montana Hematology/Oncology Centers of the Northern Rockies Billings, Montana, United States, 59101 United States, Nevada Nevada Cancer Institute Las Vegas, Nevada, United States, 89135 United States, New York Queens Medical Associates, PC Fresh Meadows, New York, United States, 11365 Long Island Jewish Medical Center New Hyde Park, New York, United States, 11040 NYU Medical Center New York, New York, United States, 10016 James P. Wilmot Cancer Center/University of Rochester Rochester, New York, United States, 14642 United States, North Carolina Raleigh Hematology/Oncology Clinic Cary, North Carolina, United States, 27511 Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Oklahoma Cancer Care Associates/Oklahoma City Oklahoma City, Oklahoma, United States, 73112 Cancer Care Associates--Tulsa Tulsa, Oklahoma, United States, 74136 United States, South Carolina Cancer Centers of the Carolinas Seneca, South Carolina, United States, 29672 United States, Texas Texas Cancer Center/Abilene Abilene, Texas, United States, 79606-5208 MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Virginia Virginia Oncology Associates-Lake Wright Cancer Center Norfolk, Virginia, United States, 23502 Less <<
NCT00116389	Pancreatic Cancer ... More >> Neoplasm Metastasis Adenocarcinoma Less <<	Phase 2	Terminated(FDA Hold May 2007)	-	-
NCT00243204	Carcinoma, Non-Small Cell Lung	Phase 3	Terminated(FDA Hold May 2007)	-	-
NCT00303940	Brain and Central Nervous Syst... More >>em Tumors Childhood Germ Cell Tumor Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Sarcoma Unspecified Childhood Solid Tumor, Protocol Specific Less <<	Phase 1	Completed	-	United States, Maryland ... More >> Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182 Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	3.22mL 0.64mL 0.32mL	16.12mL 3.22mL 1.61mL	32.24mL 6.45mL 3.22mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2 The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed